Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00425477 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions

BIOLOGICAL: sargramostim
DRUG: bexarotene
GENETIC: cytogenetic analysis
GENETIC: fluorescence in situ hybridization
OTHER: flow cytometry
OTHER: laboratory biomarker analysis
PROCEDURE: biopsy

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]